Explore All Access
Check if your research matches the topics covered in IMMUNOTARGETS AND THERAPY?
- Degree of match
- Common matching concepts
- Additional journal recommendations
IMMUNOTARGETS AND THERAPY : Impact Factor & More
eISSN: 2253-1556pISSN: 2253-1556
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
IMMUNOTARGETS AND THERAPY Key Metrics
Time to Accept 
3
Mo
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months23%
4 to 6 months74%
7 to 9 months3%
Above 9 months0%
Did you find this useful?
Topics Covered on IMMUNOTARGETS AND THERAPY
Antigen
Acetylcholine
Janus kinase inhibitor
Immune checkpoint inhibitors
Food allergy
Yersinia pestis
Pulmonary pathology
Chimeric antigen receptor
Immunotherapy
IMMUNOTARGETS AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in IMMUNOTARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in IMMUNOTARGETS AND THERAPY
Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies' Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated Disorders.
- 1 Oct 2024
- ImmunoTargets and therapy
Assessing the Prognostic Value of 13 Inflammation-Based Scores in Patients with Unresectable or Advanced Biliary Tract Carcinoma After Immunotherapy.
- 1 Oct 2024
- ImmunoTargets and therapy
The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.
- 1 Oct 2024
- ImmunoTargets and therapy
Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment.
- 1 Oct 2024
- ImmunoTargets and therapy
Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.
- 1 Sep 2024
- ImmunoTargets and therapy
Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study.
- 1 Aug 2024
- ImmunoTargets and therapy
Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies' Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated Disorders.
- 1 Oct 2024
- ImmunoTargets and therapy
Assessing the Prognostic Value of 13 Inflammation-Based Scores in Patients with Unresectable or Advanced Biliary Tract Carcinoma After Immunotherapy.
- 1 Oct 2024
- ImmunoTargets and therapy
The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.
- 1 Oct 2024
- ImmunoTargets and therapy
Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment.
- 1 Oct 2024
- ImmunoTargets and therapy
Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.
- 1 Sep 2024
- ImmunoTargets and therapy
Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study.
- 1 Aug 2024
- ImmunoTargets and therapy
Compare Similar Journals with IMMUNOTARGETS AND THERAPY
Select Journals to Compare with IMMUNOTARGETS AND THERAPY
Total journals - 8
You can select up to 3 Journals at a time
Frontiers in Immunology
Publisher: FRONTIERS MEDIA SA
International Journal of Molecular Sciences
Publisher: MDPI
Journal for ImmunoTherapy of Cancer
Publisher: BMJ PUBLISHING GROUP
Cancers
Publisher: MDPI
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Immunology
Publisher: WILEY
Journal of Allergy and Clinical Immunology
Publisher: MOSBY-ELSEVIER
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
0 Journals Selected to compare with
IMMUNOTARGETS AND THERAPY
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on IMMUNOTARGETS AND THERAPY
How long has IMMUNOTARGETS AND THERAPY been actively publishing? 
IMMUNOTARGETS AND THERAPY has been in operation since 2012 till date.
What is the publishing frequency of IMMUNOTARGETS AND THERAPY?
IMMUNOTARGETS AND THERAPY published with a Continuous publication frequency.
How many articles did IMMUNOTARGETS AND THERAPY publish last year?
In 2023, IMMUNOTARGETS AND THERAPY publsihed 14 articles.
What is the eISSN & pISSN for IMMUNOTARGETS AND THERAPY?
For IMMUNOTARGETS AND THERAPY, eISSN is 2253-1556 and pISSN is 2253-1556.
Who is the publisher of IMMUNOTARGETS AND THERAPY?
DOVE MEDICAL PRESS LTD is the publisher of IMMUNOTARGETS AND THERAPY.
